Huntsville, Ala – CFD Research has secured a competitive $1.6 million Grant from the NIH National Center for Complementary and Integrative Health (NCCIH). This significant achievement will provide nondilutive funding to advance the innovative Kalm Patch into clinical trials for the treatment of eczema and psoriasis. These trials will include safety, efficacy, and manufacturing studies conducted in alignment with FDA guidelines, further exploring the microbiome-balancing potential of the natural active ingredient. CFD Research developed Kalm patch will be commercialized by Kalm Therapeutics. (www.kalmtherapeutics.com).
Balancing the skin microbiome has been identified in numerous published studies as a promising approach to reducing the progression of eczema and psoriasis. This grant enables in-depth research into this field, supporting the development of innovative treatments that align with CFD Research’s commitment to advancing health through cutting-edge science.
The Kalm Patch, featuring “Continuous Dose” technology, delivers a 24-hour application of an anti-inflammatory and anti-Staph natural medication while protecting the skin from itching and infection. This peel-and-stick patch offers a convenient and effective alternative to traditional topical steroids, which often require multiple applications per day.
“We are honored to be selected for this competitive, peer-reviewed grant. We believe the Kalm Patch can fill a large unmet need for safer and easier eczema/psoriasis treatments. We are thankful for NCCIH’s investment and focus on natural, microbiome-modulating treatments,” said Grant Principal Investigator, AJ Singhal.
About Kalm Therapeutics: Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. The Kalm patch offers a steroid-free, natural alternative to the growing number of adults and children battling eczema.
About CFD Research: Since its inception in 1987, CFD Research has delivered innovative technology solutions within the Aerospace & Defense, Biomedical & Life Sciences, Intelligence & Sensing, and Energy & Materials industries. CFD Research has earned multiple national awards for successful application and commercialization of innovative component/system technology prototypes, multi-physics simulation software, multi-disciplinary analyses, and expert support services. Based in Huntsville, Alabama where laboratory facilities and headquarters are located, CFD Research also has office and laboratory facilities in Dayton, Ohio, prototyping test and evaluation facilities in Hollywood, Alabama, and office facilities in Fort Walton Beach, Florida. CFD Research is an ISO9001:AS9100D registered company and is appraised at CMMI Level II for Services. CFD Research is a 100% ESOP (employee-owned company) recognized in Inc. Magazine’s Inc5000 as a top growing company for four of the last five years. Learn more at www.cfd-research.com.
